Stehman-Breen C - Search Results

1

Design and methods of a postmarketing pharmacoepidemiology study assessing long-term safety of Prolia® (denosumab) for the treatment of postmenopausal osteoporosis.

Xue F, Ma H, Stehman-Breen C, Haller C, Katz L, Wagman RB, Critchlow CW; Denosumab Global Safety Assessment Team. Xue F, et al. Among authors: stehman breen c. Pharmacoepidemiol Drug Saf. 2013 Oct;22(10):1107-14. doi: 10.1002/pds.3477. Epub 2013 Jul 15. Pharmacoepidemiol Drug Saf. 2013. PMID: 23857864 Free PMC article.

2

Greater epoetin alfa responsiveness is associated with improved survival in hemodialysis patients.

Kilpatrick RD, Critchlow CW, Fishbane S, Besarab A, Stehman-Breen C, Krishnan M, Bradbury BD. Kilpatrick RD, et al. Clin J Am Soc Nephrol. 2008 Jul;3(4):1077-83. doi: 10.2215/CJN.04601007. Epub 2008 Apr 16. Clin J Am Soc Nephrol. 2008. PMID: 18417744 Free PMC article. Clinical Trial.

3

Cardiovascular and thromboembolic events following hypertensive pregnancy.

Kestenbaum B, Seliger SL, Easterling TR, Gillen DL, Critchlow CW, Stehman-Breen CO, Schwartz SM. Kestenbaum B, et al. Am J Kidney Dis. 2003 Nov;42(5):982-9. doi: 10.1016/j.ajkd.2003.07.001. Am J Kidney Dis. 2003. PMID: 14582042

4

Principles of dialysis: special issues in women.

Gipson D, Katz LA, Stehman-Breen C. Gipson D, et al. Semin Nephrol. 1999 Mar;19(2):140-7. Semin Nephrol. 1999. PMID: 10192246 Review.

5

Effects of denosumab on fracture and bone mineral density by level of kidney function.

Jamal SA, Ljunggren O, Stehman-Breen C, Cummings SR, McClung MR, Goemaere S, Ebeling PR, Franek E, Yang YC, Egbuna OI, Boonen S, Miller PD. Jamal SA, et al. Among authors: stehman breen c. J Bone Miner Res. 2011 Aug;26(8):1829-35. doi: 10.1002/jbmr.403. J Bone Miner Res. 2011. PMID: 21491487 Free article. Clinical Trial.

6

Rationale--Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT): evolving the management of cardiovascular risk in patients with chronic kidney disease.

Mix TC, Brenner RM, Cooper ME, de Zeeuw D, Ivanovich P, Levey AS, McGill JB, McMurray JJ, Parfrey PS, Parving HH, Pereira BJ, Remuzzi G, Singh AK, Solomon SD, Stehman-Breen C, Toto RD, Pfeffer MA. Mix TC, et al. Am Heart J. 2005 Mar;149(3):408-13. doi: 10.1016/j.ahj.2004.09.047. Am Heart J. 2005. PMID: 15864229

7

HMG-CoA reductase inhibitors are associated with reduced mortality in ESRD patients.

Seliger SL, Weiss NS, Gillen DL, Kestenbaum B, Ball A, Sherrard DJ, Stehman-Breen CO. Seliger SL, et al. Kidney Int. 2002 Jan;61(1):297-304. doi: 10.1046/j.1523-1755.2002.00109.x. Kidney Int. 2002. PMID: 11786112 Free article.

8

Elevated risk of stroke among patients with end-stage renal disease.

Seliger SL, Gillen DL, Longstreth WT Jr, Kestenbaum B, Stehman-Breen CO. Seliger SL, et al. Kidney Int. 2003 Aug;64(2):603-9. doi: 10.1046/j.1523-1755.2003.00101.x. Kidney Int. 2003. PMID: 12846756 Free article.

9

Risk factors for upper gastrointestinal bleeding among end-stage renal disease patients.

Wasse H, Gillen DL, Ball AM, Kestenbaum BR, Seliger SL, Sherrard D, Stehman-Breen CO. Wasse H, et al. Kidney Int. 2003 Oct;64(4):1455-61. doi: 10.1046/j.1523-1755.2003.00225.x. Kidney Int. 2003. PMID: 12969166 Free article.

10

Increased risk of mortality associated with hip fracture in the dialysis population.

Mittalhenkle A, Gillen DL, Stehman-Breen CO. Mittalhenkle A, et al. Am J Kidney Dis. 2004 Oct;44(4):672-9. Am J Kidney Dis. 2004. PMID: 15384018

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

90 results

Search Page

Filters